{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=encorafenib&page=2", "query": { "intervention": "encorafenib", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=encorafenib&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-26T20:17:25.456Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06194929", "title": "Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cutaneous Melanoma", "Brain Metastases" ], "interventions": [ { "name": "Defactinib", "type": "DRUG" }, { "name": "Avutometinib", "type": "DRUG" }, { "name": "Encorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2024-03-20", "completion_date": "2030-01-15", "has_results": false, "last_update_posted_date": "2025-12-03", "last_synced_at": "2026-09-26T20:17:25.456Z", "location_count": 2, "location_summary": "Iowa City, Iowa • Salt Lake City, Utah", "locations": [ { "city": "Iowa City", "state": "Iowa" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT06194929" }, { "nct_id": "NCT04390243", "title": "Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Pancreatic Carcinoma", "Metastatic Pancreatic Carcinoma", "Recurrent Pancreatic Carcinoma", "Stage III Pancreatic Cancer AJCC v8", "Stage IV Pancreatic Cancer AJCC v8" ], "interventions": [ { "name": "Binimetinib", "type": "DRUG" }, { "name": "Encorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Academic and Community Cancer Research United", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2020-11-16", "completion_date": "2023-11-01", "has_results": true, "last_update_posted_date": "2024-05-06", "last_synced_at": "2026-09-26T20:17:25.456Z", "location_count": 5, "location_summary": "Phoenix, Arizona • Los Angeles, California • Baltimore, Maryland + 2 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04390243" }, { "nct_id": "NCT04657991", "title": "A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Encorafenib", "type": "DRUG" }, { "name": "Binimetinib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 257, "start_date": "2021-01-15", "completion_date": "2026-10-30", "has_results": false, "last_update_posted_date": "2026-09-03", "last_synced_at": "2026-09-26T20:17:25.456Z", "location_count": 27, "location_summary": "Orlando, Florida • Fairway, Kansas • Overland Park, Kansas + 16 more", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Fairway", "state": "Kansas" }, { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04657991" }, { "nct_id": "NCT01543698", "title": "A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumors Harboring a BRAF V600 Mutation" ], "interventions": [ { "name": "LGX818", "type": "DRUG" }, { "name": "MEK162", "type": "DRUG" }, { "name": "LEE011", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 189, "start_date": "2012-05-28", "completion_date": "2023-03-09", "has_results": true, "last_update_posted_date": "2024-03-13", "last_synced_at": "2026-09-26T20:17:25.456Z", "location_count": 6, "location_summary": "Tampa, Florida • Baltimore, Maryland • Boston, Massachusetts + 1 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01543698" }, { "nct_id": "NCT03864042", "title": "Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Metastatic Melanoma" ], "interventions": [ { "name": "losartan", "type": "DRUG" }, { "name": "dextromethorphan", "type": "DRUG" }, { "name": "caffeine", "type": "DRUG" }, { "name": "omeprazole", "type": "DRUG" }, { "name": "midazolam", "type": "DRUG" }, { "name": "rosuvastatin", "type": "DRUG" }, { "name": "bupropion immediate release (IR)", "type": "DRUG" }, { "name": "encorafenib", "type": "DRUG" }, { "name": "binimetinib", "type": "DRUG" }, { "name": "modafinil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2018-01-02", "completion_date": "2023-05-29", "has_results": true, "last_update_posted_date": "2024-09-27", "last_synced_at": "2026-09-26T20:17:25.456Z", "location_count": 11, "location_summary": "Orange, California • Aurora, Colorado • Chicago, Illinois + 7 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Hopkins", "state": "Minnesota" }, { "city": "Maple Grove", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03864042" }, { "nct_id": "NCT03911869", "title": "An Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain Metastasis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain Metastases" ], "interventions": [ { "name": "encorafenib", "type": "DRUG" }, { "name": "binimetinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2019-04-30", "completion_date": "2022-01-27", "has_results": true, "last_update_posted_date": "2023-05-31", "last_synced_at": "2026-09-26T20:17:25.456Z", "location_count": 11, "location_summary": "Los Angeles, California • San Francisco, California • Santa Monica, California + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03911869" }, { "nct_id": "NCT01436656", "title": "A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma and Metastatic Colorectal Cancer" ], "interventions": [ { "name": "LGX818", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 107, "start_date": "2011-09-05", "completion_date": "2022-11-07", "has_results": true, "last_update_posted_date": "2024-10-28", "last_synced_at": "2026-09-26T20:17:25.456Z", "location_count": 5, "location_summary": "Tampa, Florida • Boston, Massachusetts", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01436656" }, { "nct_id": "NCT05954546", "title": "A Study to Compare How Effective is Encorafenib Plus Binimetinib in Real-world and Clinical Trial Settings", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Metastatic Melanoma" ], "interventions": [ { "name": "Enco+bini", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 275, "start_date": "2023-07-21", "completion_date": "2023-12-31", "has_results": true, "last_update_posted_date": "2025-02-05", "last_synced_at": "2026-09-26T20:17:25.456Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05954546" }, { "nct_id": "NCT05217446", "title": "A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "Encorafenib", "type": "DRUG" }, { "name": "Cetuximab", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 108, "start_date": "2022-07-11", "completion_date": "2027-01-26", "has_results": false, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-09-26T20:17:25.456Z", "location_count": 6, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Miami Beach, Florida + 2 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Miami Beach", "state": "Florida" }, { "city": "Germantown", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05217446" }, { "nct_id": "NCT03026517", "title": "Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Dabrafenib", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" }, { "name": "Phenformin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2017-01", "completion_date": "2025-01-21", "has_results": false, "last_update_posted_date": "2025-01-23", "last_synced_at": "2026-09-26T20:17:25.456Z", "location_count": 3, "location_summary": "Boston, Massachusetts • Harrison, New York • New York, New York", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Harrison", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03026517" } ] }